Intellia (NTLA) is a publicly traded Healthcare sector company. As of May 20, 2026, NTLA trades at $12.38 with a market cap of $1.77B and a P/E ratio of -3.48. NTLA moved +2.68% today. Year to date, NTLA is +30.84%; over the trailing twelve months it is +26.78%. Its 52-week range spans $5.90 to $28.25. Analyst consensus is buy with an average price target of $21.06. Rallies surfaces NTLA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Intellia’s Lonvo-z Cuts Attacks 87%, Initiates BLA Submission and Raises $207M: Intellia’s Phase 3 HAELO trial of lonvo-z cut hereditary angioedema attacks by 87% versus placebo over six months with favorable safety, prompting a rolling BLA submission targeting potential U.S. approval in H1 2027. The company raised $207 million in April and held $517.2 million in cash at quarter-end, funding operations into 2028.
| Metric | Value |
|---|---|
| Price | $12.38 |
| Market Cap | $1.77B |
| P/E Ratio | -3.48 |
| EPS | $-3.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.25 |
| 52-Week Low | $5.90 |
| Volume | 3.64M |
| Avg Volume | 0 |
| Revenue (TTM) | $66.09M |
| Net Income | $-394.60M |
| Gross Margin | 0.00% |
19 analysts cover NTLA: 0 strong buy, 9 buy, 8 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.06.